Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depot buprenorphine versus oral methadone for opioid use disorder in adults in custody
ACTRN12618000942257Phase 3Completed
- Sponsor
- NSW Ministry of Health
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of CAM2038 and methadone in opioid use disorder (OUD) (2 arms), sponsored by NSW Ministry of Health. Primary endpoints: Adverse events and serious adverse events, Incidents of diversion during dosing and 1 more. Started Nov 2018; status: completed.
02
Drugs
CAM2038methadone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12618000942257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000942257.